EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

David A Sallman iD, Monzr M Al Malki iD, Adam S Asch, Eunice S Wang iD, Joseph G Jurcic, Terrence J Bradley, Ian W Flinn iD, Daniel A Pollyea iD, Suman Kambhampati, Tiffany N Tanaka iD, Joshua F Zeidner iD, Guillermo Garcia-Manero iD und 13 weitere

Journal of Clinical Oncology · 20.05.2023 · 41 (15) · 2815-2826

DOI: 10.1200/jco.22.01794 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2023. Verfasst von David A Sallman und 24 weiteren Autor:innen. Beteiligte Einrichtung: Moffitt Cancer Center, Tampa, FL. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 195-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. We report final phase Ib data in patients with untreated higher-risk myelodysplastic syndromes (MDS) treated with magrolimab and azacitidine (ClinicalTrials.gov identifier: NCT03248479 ). PATIENTS AND METHODS Patients with previously untreated Revised International Prognostic Scoring System intermediate-/high-/very high-risk MDS received magrolimab intravenously as a priming dose (1 mg/kg) followed by ramp-up to a 30 mg/kg once‐weekly or once‐every-2-week maintenance dose. Azacitidine 75 mg/m 2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and complete remission (CR) rate. RESULTS Ninety-five patients were treated. Revised International Prognostic Scoring System risk was intermediate/high/very high in 27%, 52%, and 21%, respectively. Fifty-nine (62%) had poor-risk cytogenetics and 25 (26%) had TP53 mutation. The most common treatment-emergent adverse effects included constipation (68%), thrombocytopenia (55%), and anemia (52%). Median hemoglobin change from baseline to first postdose assessment was −0.7 g/dL (range, −3.1 to +2.4). CR rate and overall response rate were 33% and 75%, respectively. Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. Median overall survival (OS) was not reached with 17.1-month follow-up. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. CONCLUSION Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. A phase III trial of magrolimab/placebo + azacitidine is ongoing (ClinicalTrials.gov identifier: NCT04313881 [ENHANCE]).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansAzacitidineAntibodies, Monoclonal, HumanizedProgression-Free SurvivalTreatment Outcome

Substanzen

AzacitidinemagrolimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Moffitt Cancer Center, Tampa, FL.
  • City of Hope National Medical Center, Duarte, CA.
  • Stephenson Cancer Center-University of Oklahoma Health Sciences Center, Oklahoma City, OK.
  • Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Columbia University Medical Center, New York, NY.
  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.

ORCID-Profile: David A Sallman, Monzr M Al Malki, Eunice S Wang, Ian W Flinn, Daniel A Pollyea, Tiffany N Tanaka, Joshua F Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Rami Komrokji, Hagop M Kantarjian, Paresh Vyas, Naval G Daver

Förderung

  • NCI NIH HHS

Zitieren

APA

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Komrokji, R., Lancet, J., Kantarjian, H. M., Gu, L., Zhang, Y., Tan, A., …, & Daver, N. G. (2023). Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology, 41(15), 2815-2826. https://doi.org/10.1200/jco.22.01794

Vancouver

Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. Journal of Clinical Oncology. 2023;41(15):2815-2826. doi:10.1200/jco.22.01794

BibTeX
@article{Sallman2023,
  author = {Sallman, David A and Al Malki, Monzr M and Asch, Adam S and Wang, Eunice S and Jurcic, Joseph G and Bradley, Terrence J and Flinn, Ian W and Pollyea, Daniel A and Kambhampati, Suman and Tanaka, Tiffany N and Zeidner, Joshua F and Garcia-Manero, Guillermo and Jeyakumar, Deepa and Komrokji, Rami and Lancet, Jeffrey and Kantarjian, Hagop M and Gu, Lin and Zhang, Yajia and Tan, Anderson and Chao, Mark and O'Hear, Carol and Ramsingh, Giridharan and Lal, Indu and Vyas, Paresh and Daver, Naval G},
  title = {Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {15},
  pages = {2815--2826},
  doi = {10.1200/jco.22.01794}
}
Kostenlos starten →